Smart Delivery Vehicles for Cancer: Categories, Unique Roles and Therapeutic Strategies

Overview

Journal Nanoscale Adv

Publisher Royal Society of Chemistry

Specialty Biotechnology

Date 2024 Aug 22

PMID 39170969

Authors

Yiyu Zeng

Yijun Gao

Liming He

Wenhui Ge

Xinying Wang

Tao Ma

Xiaoyan Xie

Affiliations

Soon will be listed here.

Abstract

Chemotherapy and surgery remain the primary treatment modalities for cancers; however, these techniques have drawbacks, such as cancer recurrence and toxic side effects, necessitating more efficient cancer treatment strategies. Recent advancements in research and medical technology have provided novel insights and expanded our understanding of cancer development; consequently, scholars have investigated several delivery vehicles for cancer therapy to improve the efficiency of cancer treatment and patient outcomes. Herein, we summarize several types of smart therapeutic carriers and elaborate on the mechanism underlying drug delivery. We reveal the advantages of smart therapeutic carriers for cancer treatment, focus on their effectiveness in cancer immunotherapy, and discuss the application of smart cancer therapy vehicles in combination with other emerging therapeutic strategies for cancer treatment. Finally, we summarize the bottlenecks encountered in the development of smart cancer therapeutic vehicles and suggest directions for future research. This review will promote progress in smart cancer therapy and facilitate related research.

Citing Articles

Cellulose Based Nano-Scaffolds for Targeted Cancer Therapies: Current Status and Future Perspective.

Li Y, Liu W, Wang Y, Lu S Int J Nanomedicine. 2025; 20():199-213.

PMID: 39802388 PMC: 11721505. DOI: 10.2147/IJN.S500261.

Tumor-Targeted Cell-Penetrating Peptides Reveal That Monomethyl Auristatin E Temporally Modulates the Tumor Immune Microenvironment.

Mortaja M, Cheng M, Ali A, Lesperance J, Hingorani D, Allevato M Molecules. 2024; 29(23).

PMID: 39683778 PMC: 11643828. DOI: 10.3390/molecules29235618.

Nanomedicine for cancer patient-centered care.

Sorrentino C, Ciummo S, Fieni C, Di Carlo E MedComm (2020). 2024; 5(11):e767.

PMID: 39434967 PMC: 11491554. DOI: 10.1002/mco2.767.

References

Sharma P, Hu-Lieskovan S, Wargo J, Ribas A . Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy. Cell. 2017; 168(4):707-723. PMC: 5391692. DOI: 10.1016/j.cell.2017.01.017. View

Fukumura D, Kloepper J, Amoozgar Z, Duda D, Jain R . Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges. Nat Rev Clin Oncol. 2018; 15(5):325-340. PMC: 5921900. DOI: 10.1038/nrclinonc.2018.29. View

Jiang R, Lonnerdal B . Bovine lactoferrin and lactoferricin exert antitumor activities on human colorectal cancer cells (HT-29) by activating various signaling pathways. Biochem Cell Biol. 2017; 95(1):99-109. DOI: 10.1139/bcb-2016-0094. View

Ratajczak K, Grel H, Olejnik P, Jakiela S, Stobiecka M . Current progress, strategy, and prospects of PD-1/PDL-1 immune checkpoint biosensing platforms for cancer diagnostics, therapy monitoring, and drug screening. Biosens Bioelectron. 2023; 240:115644. DOI: 10.1016/j.bios.2023.115644. View

Wu Z, Wu Y, He W, Lin X, Sun J, He Q . Self-propelled polymer-based multilayer nanorockets for transportation and drug release. Angew Chem Int Ed Engl. 2013; 52(27):7000-3. DOI: 10.1002/anie.201301643. View

Bukhari S, Imam S, Ahmad M, Vuddanda P, Alshehri S, Mahdi W . Recent Progress in Lipid Nanoparticles for Cancer Theranostics: Opportunity and Challenges. Pharmaceutics. 2021; 13(6). PMC: 8226834. DOI: 10.3390/pharmaceutics13060840. View

Barberio A, Smith S, Pires I, Iyer S, Reinhardt F, Melo M . Layer-by-layer interleukin-12 nanoparticles drive a safe and effective response in ovarian tumors. Bioeng Transl Med. 2023; 8(2):e10453. PMC: 10013828. DOI: 10.1002/btm2.10453. View

Hsieh Y, Hsiao Y, Jan J . Shell and core cross-linked poly(L-lysine)/poly(acrylic acid) complex micelles. Soft Matter. 2014; 10(47):9568-76. DOI: 10.1039/c4sm02033b. View

Semcheddine F, Guissi N, Liu W, Tayyaba , Gang L, Jiang H . Rapid and label-free cancer theranostics bio-self-assembled DNA-gold nanostructures loaded exosomes. Mater Horiz. 2021; 8(10):2771-2784. DOI: 10.1039/d1mh00880c. View

10.

Guo L, Qin X, Xue L, Yang J, Zhang Y, Zhu S . A novel form of docetaxel polymeric micelles demonstrates anti-tumor and ascites-inhibitory activities in animal models as monotherapy or in combination with anti-angiogenic agents. Front Pharmacol. 2022; 13:964076. PMC: 9449419. DOI: 10.3389/fphar.2022.964076. View

11.

Dong X, Liu H, Feng H, Yang S, Liu X, Lai X . Enhanced Drug Delivery by Nanoscale Integration of a Nitric Oxide Donor To Induce Tumor Collagen Depletion. Nano Lett. 2019; 19(2):997-1008. DOI: 10.1021/acs.nanolett.8b04236. View

12.

Ayoub N . Editorial: Novel Combination Therapies for the Treatment of Solid Cancers. Front Oncol. 2021; 11:708943. PMC: 8250861. DOI: 10.3389/fonc.2021.708943. View

13.

Narmani A, Yavari K, Mohammadnejad J . Imaging, biodistribution and in vitro study of smart Tc-PAMAM G4 dendrimer as novel nano-complex. Colloids Surf B Biointerfaces. 2017; 159:232-240. DOI: 10.1016/j.colsurfb.2017.07.089. View

14.

Michlewska S, Maly M, Wojkowska D, Karolczak K, Skiba E, Holota M . Carbosilane ruthenium metallodendrimer as alternative anti-cancer drug carrier in triple negative breast cancer mouse model: A preliminary study. Int J Pharm. 2023; 636:122784. DOI: 10.1016/j.ijpharm.2023.122784. View

15.

Erez A, DeBerardinis R . Metabolic dysregulation in monogenic disorders and cancer - finding method in madness. Nat Rev Cancer. 2015; 15(7):440-8. DOI: 10.1038/nrc3949. View

16.

Rogosnitzky M, Branch S . Gadolinium-based contrast agent toxicity: a review of known and proposed mechanisms. Biometals. 2016; 29(3):365-76. PMC: 4879157. DOI: 10.1007/s10534-016-9931-7. View

17.

Zhang J, Lin Y, Lin Z, Wei Q, Qian J, Ruan R . Stimuli-Responsive Nanoparticles for Controlled Drug Delivery in Synergistic Cancer Immunotherapy. Adv Sci (Weinh). 2021; 9(5):e2103444. PMC: 8844476. DOI: 10.1002/advs.202103444. View

18.

Kiaie S, Salehi-Shadkami H, Sanaei M, Azizi M, Shokrollahi Barough M, Nasr M . Nano-immunotherapy: overcoming delivery challenge of immune checkpoint therapy. J Nanobiotechnology. 2023; 21(1):339. PMC: 10512572. DOI: 10.1186/s12951-023-02083-y. View

19.

Guo J, Yu Z, Sun D, Zou Y, Liu Y, Huang L . Two nanoformulations induce reactive oxygen species and immunogenetic cell death for synergistic chemo-immunotherapy eradicating colorectal cancer and hepatocellular carcinoma. Mol Cancer. 2021; 20(1):10. PMC: 7786897. DOI: 10.1186/s12943-020-01297-0. View

20.

He Y, Xu Z, He Y, Cao G, Ni S, Tang Y . MoS nanoflower-mediated enhanced intratumoral penetration and piezoelectric catalytic therapy. Biomaterials. 2022; 290:121816. DOI: 10.1016/j.biomaterials.2022.121816. View